235 related articles for article (PubMed ID: 22872647)
1. A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine.
Heo J; Park JY; Lee HJ; Tak WY; Um SH; Kim DY; Yoon KT; Park SY; Seo YS; Han KH; Cho M; Ahn SH
Antivir Ther; 2012; 17(8):1563-70. PubMed ID: 22872647
[TBL] [Abstract][Full Text] [Related]
2. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
Chang TT; Gish RG; de Man R; Gadano A; Sollano J; Chao YC; Lok AS; Han KH; Goodman Z; Zhu J; Cross A; DeHertogh D; Wilber R; Colonno R; Apelian D;
N Engl J Med; 2006 Mar; 354(10):1001-10. PubMed ID: 16525137
[TBL] [Abstract][Full Text] [Related]
3. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
Sherman M; Yurdaydin C; Simsek H; Silva M; Liaw YF; Rustgi VK; Sette H; Tsai N; Tenney DJ; Vaughan J; Kreter B; Hindes R;
Hepatology; 2008 Jul; 48(1):99-108. PubMed ID: 18537189
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
[TBL] [Abstract][Full Text] [Related]
5. A 96-week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy.
Ahn SH; Heo J; Park JY; Woo HY; Lee HJ; Tak WY; Um SH; Yoon KT; Park SY; Kim CW; Kim HH; Han KH; Cho M
J Gastroenterol Hepatol; 2016 Apr; 31(4):865-71. PubMed ID: 26572068
[TBL] [Abstract][Full Text] [Related]
6. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
Lai CL; Shouval D; Lok AS; Chang TT; Cheinquer H; Goodman Z; DeHertogh D; Wilber R; Zink RC; Cross A; Colonno R; Fernandes L;
N Engl J Med; 2006 Mar; 354(10):1011-20. PubMed ID: 16525138
[TBL] [Abstract][Full Text] [Related]
7. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.
Lai CL; Rosmawati M; Lao J; Van Vlierberghe H; Anderson FH; Thomas N; Dehertogh D
Gastroenterology; 2002 Dec; 123(6):1831-8. PubMed ID: 12454840
[TBL] [Abstract][Full Text] [Related]
8. Antiviral effect of entecavir in nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy.
Chen CH; Hu TH; Hung CH; Wang JH; Lu SN; Lee CM
J Viral Hepat; 2014 Aug; 21(8):e55-64. PubMed ID: 24766327
[TBL] [Abstract][Full Text] [Related]
9. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
[TBL] [Abstract][Full Text] [Related]
10. Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.
Lim YS; Lee TH; Heo NY; Shim JH; Lee HC; Suh DJ
Antivir Ther; 2012; 17(1):53-60. PubMed ID: 22267469
[TBL] [Abstract][Full Text] [Related]
11. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine.
Lo AO; Wong VW; Wong GL; Chan HY; Cheung CM; Chan HL
Antivir Ther; 2013; 18(5):671-9. PubMed ID: 23462214
[TBL] [Abstract][Full Text] [Related]
14. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
[TBL] [Abstract][Full Text] [Related]
15. Entecavir maleate versus entecavir in Chinese chronic hepatitis B predominantly genotype B or C: Results at week 144.
Xu JH; Wang S; Xu ZN; Yu YY; Si CW; Zeng Z; Li J; Mao Q; Zhang DZ; Tang H; Sheng JF; Chen XY; Ning Q; Shi GF; Xie Q; Zhang XQ; Dai J
J Viral Hepat; 2017 Oct; 24(10):877-884. PubMed ID: 28345157
[TBL] [Abstract][Full Text] [Related]
16. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.
Lim YS; Lee JY; Lee D; Shim JH; Lee HC; Lee YS; Suh DJ
Antimicrob Agents Chemother; 2013 Jul; 57(7):3369-74. PubMed ID: 23650172
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: outcome at 2 Years.
Fung J; Lai CL; Yuen J; Cheng C; Wu R; Wong DK; Seto WK; Hung IF; Yuen MF
Hepatology; 2011 Apr; 53(4):1148-53. PubMed ID: 21480321
[TBL] [Abstract][Full Text] [Related]
19. Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial.
Yim HJ; Seo YS; Yoon EL; Kim CW; Lee CD; Park SH; Lee MS; Park CK; Chae HB; Kim MY; Baik SK; Kim YS; Kim JH; Lee JI; Lee JW; Hong SP; Um SH
Liver Int; 2013 Feb; 33(2):244-54. PubMed ID: 23295056
[TBL] [Abstract][Full Text] [Related]
20. Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir.
Lee JM; Kim HJ; Park JY; Lee CK; Kim DY; Kim JK; Lee HW; Paik YH; Lee KS; Han KH; Chon CY; Hong SP; Nguyen T; Ahn SH
Antivir Ther; 2009; 14(5):705-12. PubMed ID: 19704174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
